Moving to human iPSC-derived cells is a big step, but you don’t take it alone. From finding funding opportunities and relevant events, to clear user manuals, optimised application protocols, and responsive, hands-on technical support, we’re with you every step of the way.
Reach out to start your journey and join the community of scientists advancing the adoption of human cells.
Understanding and applying human iPSC-derived cells
Read insights from policy, academia, and industry. These blogs explore why the transition to human-specific research is accelerating, the importance of reproducibility, and how iPSC-derived cells are being used to improve drug discovery outcomes.
Funding opportunities to support the reduction and replacement of animal research across the UK, Europe, the US and Canada.
| Region | Funding Body | Funding Type / Purpose | Grant / Prize Size | Deadline | Additional info |
| UK | Animal welfare / 3R projects (refinement, replacement, education, publications) | Substantial awards (over £3,500) for major projects | Anytime (with at least 2 months’ lead before project start) | Good for small-scale/ medium-scale 3R or welfare-related studies | |
| UK | Animal welfare / 3R projects (refinement, replacement, education, publications) | Smaller grants via Small Project / Travel Awards for < £3,500 | Anytime (with at least 2 months’ lead before project start) | Good for small-scale/ medium-scale 3R or welfare-related studies | |
| UK | Animal-free biomedical research project grants and fellowships | ~ £90,000 - £200,000 | Project-grant call opens 2 Feb 2026; closes 24 May 2026 | Supports fully animal-free disease-focused research. | |
| UK | Innovation Grants (pilot studies) | Small grants ~ £5,000 | 2025 round closed; next call not yet announced for 2026 | Supports proof-of-principle animal-free method development. | |
| Germany | Research / young-researcher award in systems medicine / 3R-relevant biomedical research | €15,000 | 31-Jan-26 | Suitable for system-oriented health / biomedical projects with 3R relevance | |
| Germany | Molecular-biology research on disease mechanisms (cell and/or human tissue-based, could partly involve animal models but requires human tissue/cell component) | Not specified | 01-Feb-26 | Could fit human iPSC / cell-based disease-mechanism modelling | |
| Germany | Funding for alternative (non-animal) methods: replacement, validation, dissemination of 3R-methods | Not specified | 15-Mar-26 | Directly relevant to non-animal / replacement method development | |
| Germany | Research or welfare-oriented work aimed at replacing or reducing animal testing, or improving animal welfare in labs | Up to €30,000 | 30 Sep 2026 | Good for substantial projects in replacement/ refinement/ welfare | |
| Europe | Support research groups that have demonstrated an ongoing commitment to the adoption of human-specific research. | Not specified | Coming soon in 2026 | ||
| Europe | Grants for young scientists to develop/test Replacement, Reduction and/or Refinement methods (3R projects) | € 3,000 | For projects starting 2026; application deadline 31 Oct 2025 (4 pm CET) | Good entry-level funding for 3R method development | |
| Europe | Grants for science communication / outreach / transparency related to animal research / 3R awareness / tools & resources | Up to €3,000 | For projects starting 2025; application deadline 31 Oct 2025 | Useful for educational / outreach / science-communication 3R initiatives | |
| USA | Annual Open Grant Program | Up to $50,000 | Next call expected early 2026 | Supports the development of non-animal research/testing methods. | |
| USA | Research grants supporting development of non‑animal methods | Up to $40,000 | Annual cycles; ongoing into 2026 | Supports in vitro assays, AOP development, and mechanistic toxicology | |
| USA | Reduction-focused research (meta‑analysis, reproducibility, model reevaluation) | Varies | Available; 2025/26 cycle active or recurring | Supports projects evaluating the limitations of animal models | |
| USA | Development of animal‑free teaching and training resources | ~$6,000 | Available; recurring annually | Supports the creation of human‑relevant training tools |
Learn from your peers
Here are some of the top conferences and events to attend to learn about how peers are utilising human iPSC-derived cells and new techniques being developed to support the integration of iPSC-derived cells.
| Conference | Dates | Location |
| Feb 4–5 2026 | Cambridge, UK | |
| Feb 7–11 2026 | Boston, MA, USA | |
| Feb 12–13 2026 | Oslo, Norway | |
| Mar 10–12 2026 | Raleigh, NC, USA | |
| Mar 22–25 2026 | San Diego, CA, USA | |
| Mar 24–27 2026 | Tübingen, Germany | |
| Apr 17–22 2026 | San Diego, CA, USA | |
| Apr 20–24 2026 | Palma, Spain | |
| May 7–8 2026 | London, UK | |
| May 19–21 2026 | Vienna, Austria | |
| May 26–29 2026 | Washington, D.C., USA | |
| Jun 22–24 2026 | Braga, Portugal | |
| Jun 29 – Jul 2 2026 | Maastricht, NL | |
| Jul 8–11 2026 | Montreal, Canada | |
| Nov 14–18 2026 | Washington, D.C., USA | |
| Dec 12–16 2026 | San Diego, CA, USA |
Flexible training options: join us virtually or in person
Master your workflows with our protocol library
To get your lab up and running with human iPSC-derived ioCells, you will need the following equipment.
| Equipment | Necessity | Reason |
| Class II Biosafety Cabinet | Required | Protects cells from contamination and you from human pathogens. |
| Liquid nitrogen storage | Required | -80°C is for short-term (days) only; liquid nitrogen is for long-term. |
| Automated cell counter | Highly recommended |
Vital for plating exact densities (e.g. neurons and microglia are sensitive to 'crowding').
|
| Water bath | Required |
Essential for rapid thawing at 37°C. When using water bath, meticulously clean it weekly to prevent "water-to-hood" contamination.
|
| Centrifuge | Required | Must have a swing-bucket rotor and adjustable "braking" speeds to prevent mechanical stress on fragile cells. |
| Pipettes | Required | Use high-precision P1000/P200 sets. Ergonomic electronic pipettes are preferred for "slow-dispense" modes. |
| Phase contrast microscope | Required | Vital for daily monitoring of attachment, health, and potential contamination. |
Do I need a specialised incubator?
No, a standard 37oC, 5% CO2 incubator works fine. You will need to incorporate strict rules for cleanliness and humidity management, as iPSC-derived cells can be in culture for a long time (weeks to months).
Cleanliness
Humidity management
Because these cultures stay in the incubator for long periods, even tiny amounts of evaporation can be fatal.
To prevent increased osmolarity, ensure your incubator has a high-quality water pan (using sterile, ultra-pure water with an antimicrobial additive like Aquaguard) and minimise door-opening frequency to keep humidity at 95%.
How do I store human iPSC-derived cells?
The cell must be store in liquid nitrogen.
Never store iPSC-derived cells in a -80oC freezer for longer than 24 hours. Even a "stable" -80oC can fluctuate, causing microscopic ice recrystallisation that kills post-mitotic cells.
The vapour phase of liquid nitrogen (-150oC to -190oC) is preferred over immersion to avoid the rare risk of "exploding vials" or cross-contamination through the vial caps.
What biosafety requirements should I consider for commercial human iPSC-derived cells?
Containment Level: Commercial human iPSC-derived cells are handled under Biosafety Level 2 (BSL-2) containment. Even if the cells are "commercial," human-derived materials are treated as potentially infectious for bloodborne pathogens.
Cabinet Requirements: All cell handling, such as thawing, culture, and dissociation, should be performed in a Class II biological safety cabinet.
Personal Protective Equipment (PPE): Safety glasses, lab coats, and gloves must be worn to prevent exposure to skin, eyes, or mucous membranes.
Is my Cat 2 hood enough?
Ryan Jones, PhD
Research Associate
School of Biosciences
Cardiff University
Early-career researcher Dr Ryan Jones challenges outdated models, taking risks to drive human-specific research for real patient impact.
Mariangela Iovino, PhD
Senior Group Leader
Charles River Laboratories
Building connections with Dr Mariangela Iovino, discussing how industry experts are incorporating human cells to drive human-specific drug discovery.
Eric Hill, PhD
Reader in Cellular and Molecular Neurobiology
Loughborough University
In conversation with Dr Eric Hill we cover pushing the boundaries, culturing human neurons on a computer chip, and making AI sustainable.
Ross Dobie, PhD
Head of Science
Centre for Human Specific Research
Dr Ross Dobie explores the move to human models, covering adoption hurdles, scientific and cost challenges, supportive FDA and NIH policies, and the rise of NAMs.
Dr Michael Duchen
Professor of Physiology | University College London
Jeremy Krohn
PhD Candidate | DZNE / Charité University of Medicine
Dr Marijn Vlaming
Head of Biology - Beerse & Leiden | Charles River
Matteo Zanella, PhD
Associate Research Leader | Charles River
Dr Alessandra Pagliaro
Research scientist | In Vitro Biology | Evotec
ioWild Type Cells
ioWild Type Cells are defined, easy-to-use, functional iPSC-derived human cells from a healthy donor background that are ready for fundamental research and drug discovery experimentation within days.
ioDisease Model Cells
ioDisease Model Cells are ioWild Type Cells engineered to contain disease-relevant mutations. ioDisease Model Cells and ioWild Type Cells form an isogenic pair allowing scientists to make true comparisons.
CRISPR-Ready ioCells
CRISPR-Ready ioCells are human iPSC-derived cells constitutively expressing Cas9 nuclease for rapid gene knockout generation.
ioTracker Cells
ioTracker Cells are human iPSC-derived cells constitutively expressing a fluorescent protein for easy visualisation, tracking, and isolation of human cells in live-cell imaging assays.